- Email: [email protected]
5378625 Bacillus thuringiensis cryIIIC, (b) protein toxic to coleopteran insects
PATENT ABSTRACTS Disclosed herein are derivatives of Streptolysin 0 produced by recombinant DNA techniques. In an embodiment, the derivative is soluble upon expression and has a specific hemolytic activity of about 3.6"104 hemolytic units per milligram.
5378625 BACILLUS THURINGIENSIS CRYIIIC, (B) PROTEIN TOXIC TO COLEOPTERAN INSECTS Donovan William P; Rupar Mark J; Slaney Annette C Levittown~ PA, UNITED STATES Assigned to Ecogen inc A Bacillus thuringiensis s~rain isolate, designated EG5144, exhibits insecticidal activity against coleopteran insects, including Colorado potato beetle and insects of the genus Diabrotica. A novel toxin gene in B.t. strain EG5144 produces an irregularly shaped insecticidal crystal protein of approximately 70 kDa that is toxic to coleopteran insects. The cryIII-type gene (SEQ ID NO:l), designated as the cryIIIC(b) gene, has a nucleotide base sequence illustrated in FIG. 1.
5378806 FUSION PROTEIN PRODUCED BY RETROVIRUS-MEDIATED SECRETION
727
retrovirus-mediated secretion and uses of these particles for protein purification and in therapeutics.
5378808 RECOMBINANT ERYTHROPOIETIN RECEPTOR PROTEIN D'Andrea Ala; Wong Gordon G; Jones Simon S Winchester, MA, UNITED STATES Assigned to Genetics Institute Inc The invention described encompasses an isolated DNA sequence encoding all or a portion thereof of a cell surface receptor murine and human erythropoietin (hereinafter EPO-R), along with the isolated polypeptide expressed by the DNA sequence (i.e., isolated EPG-R). The invention also encompasses host cells containing the abovedescribed DNA sequence, preferably, host cells which express the polypeptide encoded by the DNA sequence (EPO-R) at a significantly higher level than that produced by normal red blood cell prec~sors. The invention further encompasses DNA sequences encoding secreted forms of the human EPO-R and polypeptides corresponding thereto. The EPO-receptor in all of the disclosed forms can be used as models for designing drugs or in pharmaceutical compositions for treating anemias.
5378810 Willis John W Shreveport, LA, UNITED STATES Assigned to Research Corporation Technologies inc The present invention is directed to replicable expression vectors for producing fusion proteins which are secreted in membraneous particles budded from the cell membrane. In particular these vectors express a hybrid gene product composed of a modified retrovirus gag gene fused a heterologous gene, or any part thereof, wherein the gag gene modification is sufficient to enable a cell to produce the hybrid gene product in a membraneous particle by budding from the cell membrane into the culture medium or extracellular space, a process known as retrovirusmediated secretion. The minimum gag sequences needed to obtain particle formation axe described. The invention also provides hosts containing the expression vectors, and the fusion proteins produced by the vectors. Further the invention provides the membraneous particlesproduced by
MUTANT SMG P21 PROTEIN WITH GTP BINDING ACTIVITY Takai Yoshimi; Kondo Jun; Matsui Yasushi; Tcranishi Yutaka; Matsui Rie Kobe, J A P A N Assigned to Mitsubishi Kasei Corporation The present invention provides a GTP binding protein containing the following amino acid sequence, with a molecular weight of about 22K dalton and having GTP binding activity which is inhibited by N-ethyl-maleimide and GTP hy&olyzing activity: Thr-lle-Glu-Aep-Ser-Tyr, and a method for the production of a GTP binding protein, which comprises introducing a DNA fragment containing DNA that encodes the GTP binding protein into a cloning site present at the downstream to a promoter of an expression vector, then introducing the expression vector thus constructed into a host, culturing said host,
5378625 BACILLUS THURINGIENSIS CRYIIIC, (B) PROTEIN TOXIC TO COLEOPTERAN INSECTS Donovan William P; Rupar Mark J; Slaney Annette C Levittown~ PA, UNITED STATES Assigned to Ecogen inc A Bacillus thuringiensis s~rain isolate, designated EG5144, exhibits insecticidal activity against coleopteran insects, including Colorado potato beetle and insects of the genus Diabrotica. A novel toxin gene in B.t. strain EG5144 produces an irregularly shaped insecticidal crystal protein of approximately 70 kDa that is toxic to coleopteran insects. The cryIII-type gene (SEQ ID NO:l), designated as the cryIIIC(b) gene, has a nucleotide base sequence illustrated in FIG. 1.
5378806 FUSION PROTEIN PRODUCED BY RETROVIRUS-MEDIATED SECRETION
727
retrovirus-mediated secretion and uses of these particles for protein purification and in therapeutics.
5378808 RECOMBINANT ERYTHROPOIETIN RECEPTOR PROTEIN D'Andrea Ala; Wong Gordon G; Jones Simon S Winchester, MA, UNITED STATES Assigned to Genetics Institute Inc The invention described encompasses an isolated DNA sequence encoding all or a portion thereof of a cell surface receptor murine and human erythropoietin (hereinafter EPO-R), along with the isolated polypeptide expressed by the DNA sequence (i.e., isolated EPG-R). The invention also encompasses host cells containing the abovedescribed DNA sequence, preferably, host cells which express the polypeptide encoded by the DNA sequence (EPO-R) at a significantly higher level than that produced by normal red blood cell prec~sors. The invention further encompasses DNA sequences encoding secreted forms of the human EPO-R and polypeptides corresponding thereto. The EPO-receptor in all of the disclosed forms can be used as models for designing drugs or in pharmaceutical compositions for treating anemias.
5378810 Willis John W Shreveport, LA, UNITED STATES Assigned to Research Corporation Technologies inc The present invention is directed to replicable expression vectors for producing fusion proteins which are secreted in membraneous particles budded from the cell membrane. In particular these vectors express a hybrid gene product composed of a modified retrovirus gag gene fused a heterologous gene, or any part thereof, wherein the gag gene modification is sufficient to enable a cell to produce the hybrid gene product in a membraneous particle by budding from the cell membrane into the culture medium or extracellular space, a process known as retrovirusmediated secretion. The minimum gag sequences needed to obtain particle formation axe described. The invention also provides hosts containing the expression vectors, and the fusion proteins produced by the vectors. Further the invention provides the membraneous particlesproduced by
MUTANT SMG P21 PROTEIN WITH GTP BINDING ACTIVITY Takai Yoshimi; Kondo Jun; Matsui Yasushi; Tcranishi Yutaka; Matsui Rie Kobe, J A P A N Assigned to Mitsubishi Kasei Corporation The present invention provides a GTP binding protein containing the following amino acid sequence, with a molecular weight of about 22K dalton and having GTP binding activity which is inhibited by N-ethyl-maleimide and GTP hy&olyzing activity: Thr-lle-Glu-Aep-Ser-Tyr, and a method for the production of a GTP binding protein, which comprises introducing a DNA fragment containing DNA that encodes the GTP binding protein into a cloning site present at the downstream to a promoter of an expression vector, then introducing the expression vector thus constructed into a host, culturing said host,